Liposome nanoparticles were then manufactured from ferroptosis-inducing PL-PUFAs, identified in the lipidomic analyses to be relatively deficient in MM cells, and loaded with the GPX4 inhibitor, RSL3. Here, GPX4 is linked to Miyoshi myopathy.